Loading
T3011 is an experimental small-molecule drug from ImmVira Pharma in phase 2 trials for melanoma, head and neck squamous cell carcinoma and sarcomas, aimed at PD-1 and PD-L1.
T3011 is a small-molecule drug developed by ImmVira Pharma and Shanghai Pharmaceuticals. Its targets are PD-1 and PD-L1. ClinicalTrials.gov describes the intervention as: T3011 will be administered up to 4mL as an intratumoral injection given Q2W. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in melanoma, head and neck squamous cell carcinoma, sarcomas, non-small-cell lung cancer and bladder & urothelial cancer. The largest, NCT06971614, plans to enrol 160 participants with primary completion expected 2028-12-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
1.T3011 slips into a pocket on PD-1.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"T3011" OR ABSTRACT:"T3011") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about T3011, not a curated reading list.
Shares ImmVira Pharma and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Melanoma, Non-small-cell lung cancer and the tag pipeline.
Shares PD-L1, PD-1, Non-small-cell lung cancer and the tag pipeline.
Shares PD-L1, PD-1, Non-small-cell lung cancer and the tag pipeline.
Shares Bladder & urothelial cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST), Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares PD-L1, PD-1, Bladder & urothelial cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Melanoma, Non-small-cell lung cancer and the tag pipeline.